Frontline Management of Atopic Dermatitis in Adults - Episode 11
ECZTEND 2-Year Interim Findings: Takeaways and Considerations
Panelists discuss how the 2-year ECZTEND study found tralokinumab effective for atopic dermatitis, with 82.5% achieving EASI-75 and 59.8%, EASI-90. Common adverse effects (AEs) included upper respiratory tract infections, dermatitis, headache, and conjunctivitis. The treatment-emergent adverse event (TEAE) withdrawal rate was 1.6%.
Video content above in prompted by the following:
- Based on the 2-year interim findings from the ECZTEND study (tralokinumab) (Blauvelt 2022), in what circumstances would you consider tralokinumab?
- Of the 291 subjects who remained in the trial for 2 years, 82.5% achieved EASI-75, and 59.8% achieved EASI-90.
- In the 1-year safety study, the most common AEs were upper respiratory tract infections, atopic dermatitis, headache, and conjunctivitis.
- 19/1174 (1.6%) withdrew due to TEAEs.
